Business Wire1h
BIOA INVESTOR ALERT: Kirby McInerney LLP Notifies BioAge Labs, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
The law firm of Kirby McInerney LLP reminds investors of the March 10, 2025, deadline to seek the role of lead plaintiff in a federal securities class ...
BIOA CLASS ACTION UPDATE: BioAge Labs Investors are Reminded to Contact BFA Law before Imminent March 10 Deadline
In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company ...
BioSpace16h
Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
MarketWatch4d
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...